Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2025-08-01 00:00:00 ET · period of report 2025-07-30 · accession 0001140361-25-028452 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-01 | 2025-07-30 | ROIV | Venker Eric | Pres, Immunovant CEO | A - Grant | $0.00 | +198.4K | 1.66M | +14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-07-30 | A | A | 198,413 | $0.00 | 1,660,636 | D | — | — | (F1) Reflects an award of restricted stock units with respect to Common Shares ("RSUs"), with a vesting commencement date of May 20, 2025, which service-vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in 12 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through each vesting date. |